Literature DB >> 26312494

The Ebola Spatial Care Path™: Accelerating point-of-care diagnosis, decision making, and community resilience in outbreaks.

Gerald J Kost1, William J Ferguson2, Jackie Hoe2, Anh-Thu Truong2, Arirat Banpavichit3, Surin Kongpila4.   

Abstract

OBJECTIVES: To present a vision where point-of-care testing (POCT) accelerates an Ebola Spatial Care Path™ (SCP) and future molecular diagnostics enable facilitated-access self-testing (FAST POC); to design an alternate care facility (ACF) for the SCP; to innovate an Ebola diagnostic center (DC); and to propel rapid POCT to the frontline to create resilience that stops future outbreaks.
DESIGN: PubMed, literature, and web searches. Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Medicine Without Frontiers, and World Health Organization (WHO) document analyses. Investigations in China, the Philippines, Thailand, and the United States. Review of SE Asia, US, and West Africa isolation-treatment centers. Innovation of a SCP, ACF, and DC suitable for American and other communities. OUTCOMES: The authors designed an ACF and DC to integrate SCP principles for urgent Ebola care. FDA emergency use authorizations for Ebola molecular diagnostics were discovered, but no portable, handheld, or self-contained molecular POC instruments are yet available, although feasible. The WHO initiated design criteria and an acceptance protocol for testing. Financial investment in POCT will downsize Ebola outbreaks.
CONCLUSIONS: POCT is facilitating global health. Now, global health problems are elevating POCT to new levels of importance for accelerating diagnosis and evidence-based decision making during disease outbreaks. Authorities concur that rapid diagnosis has potential to stop disease spread. With embedded POCT, strategic SCPs planned by communities fulfill CDC recommendations. POC devices should consolidate multiplex test clusters supporting patients with Ebola in isolation. The ultimate future solution is FAST POC. New technologies offer minimally significant risks. Diagnostic centers in ACFs and transportable formats also will optimize Ebola SCPs.

Entities:  

Mesh:

Year:  2015        PMID: 26312494     DOI: 10.5055/ajdm.2015.0196

Source DB:  PubMed          Journal:  Am J Disaster Med        ISSN: 1932-149X


  7 in total

1.  An open-source molecular diagnostic platform approach for outbreak and epidemic preparedness.

Authors:  Devy M Emperador; Laura T Mazzola; Cassandra Kelly-Cirino
Journal:  Afr J Lab Med       Date:  2020-09-28

2.  The Coronavirus Disease 2019 Spatial Care Path: Home, Community, and Emergency Diagnostic Portals.

Authors:  Gerald J Kost
Journal:  Diagnostics (Basel)       Date:  2022-05-12

Review 3.  Geospatial Science and Point-of-Care Testing: Creating Solutions for Population Access, Emergencies, Outbreaks, and Disasters.

Authors:  Gerald J Kost
Journal:  Front Public Health       Date:  2019-11-26

4.  Public Health Education Should Include Point-of-Care Testing: Lessons Learned from the Covid-19 Pandemic.

Authors:  Gerald J Kost
Journal:  EJIFCC       Date:  2021-10-18

5.  Using a geographic information system to enhance patient access to point-of-care diagnostics in a limited-resource setting.

Authors:  William J Ferguson; Karen Kemp; Gerald Kost
Journal:  Int J Health Geogr       Date:  2016-03-01       Impact factor: 3.918

6.  Point-of-Care Diagnosis of Acute Myocardial Infarction in Central Vietnam: International Exchange, Needs Assessment, and Spatial Care Paths.

Authors:  Gerald J Kost; Amanullah Zadran; Thuan T B Duong; Tung T Pham; An V D Ho; Nhan V Nguyen; Irene J Ventura; Layma Zadran; Mykhaylo V Sayenko; Kelly Nguyen
Journal:  Point Care       Date:  2018-08-27

Review 7.  Molecular detection and point-of-care testing in Ebola virus disease and other threats: a new global public health framework to stop outbreaks.

Authors:  Gerald J Kost; William Ferguson; Anh-Thu Truong; Jackie Hoe; Daisy Prom; Arirat Banpavichit; Surin Kongpila
Journal:  Expert Rev Mol Diagn       Date:  2015-09-14       Impact factor: 5.225

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.